Company latest

News and press

September 2009

New Product Launch – Ondansetron Oral Liquid…

Focus is pleased to announce the launch of Ondansetron Oral Liquid 4mg per 5ml to the market…

Full story

Directors

Mark Cresswell

Managing Director

Mark has been in the industry for almost 20 years, and has been in the generic industry for 17 years. He started at Astra Pharmaceuticals in 1990, and then moved into the generics industry in 1992 when he joined Norton Healthcare (now part of Teva) as National Accounts Manager. Since then he has held various roles at Manager and Director level at Generics UK Limited (now part of Mylan), CP Pharmaceuticals (now part of Wockhardt) and ADL Healthcare. Mark was part of the initial team that created Focus in 2003 that saw the Company become an independent entity through a management buy out.

Mark holds a BSc (Hons) in Combined Science.

Roland Brown

Marketing and Business Development Director

Roland has been in the generic industry for 17 years, holding various managerial and director-level roles in the industry. He started at Lagap (now part of Sandoz) in 1992. Roland left Lagap and worked for Hoechst Marion Roussell for a short period, before returning to Lagap in 1997. He was also Marketing Director at ADL Healthcare, where he joined in 2002. Roland was part of the initial team that created Focus in 2003 that saw the Company become an independent entity through a management buy out.

Roland holds a BA (Hons) in Economics and Geography.

Ray Maginley

Medical & Regulatory Affairs Director

Ray has been in the industry for over 27 years, starting at the R&D division of Astra in 1982. He has since held several managerial and director level roles at Norton Healthcare (now part of Teva) and Taro. Ray is a Fellow of TOPRA (The Organisation for Professionals in Regulatory Affairs) and is also a member of The Royal Society of Medicine. Ray is responsible for all aspects of Medical, Clinical and Regulatory Affairs and is the company’s designated Responsible Person. Ray’s main responsibilities revolve around bringing new products to market and ensuring the business is compliant in terms of GMP, GDP, GCP and PV.

Ray’s qualifications include a degree in Pharmaceutical Sciences and an MBA from Middlesex University.


Richard Grethe

Finance Director

Richard joined the industry in 1992 when he worked for Wellcome plc in the strategy department. He qualified as a Chartered Accountant in 1997 at KPMG, and the joined Medeva plc as a Business Analyst. He has held many roles since including Corporate Controller at Celltech plc, and UK Financial Controller at Celltech Pharma and UCB Pharma.

Richard holds a BA (Hons) in Accountancy and is an ACA.

Ashley Broomberg

Investment Director

Ashley Broomberg is a partner in Matrix Private Equity Partners LLP with over 9 years of experience investing in fast growing, privately owned businesses. He is a chartered accountant with a background in corporate finance and strategy consulting, having previously worked with Arthur D. Little and Arthur Andersen before joining Matrix in 2001. He is also currently non-executive director of VSI Limited, a software business, and Monsal Holdings, a renewable energy business.

Ashley holds a BSc in Business Science from the University of Cape Town and an MPhil in Finance from the University of Cambridge. He is an ACA